VP-16-213 salvage therapy for refractory germinal neoplasms

S. D. Williams, Lawrence Einhorn, F. A. Greco, R. Oldham, R. Fletcher

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Thirty-three patients with advanced refractory germinal neoplasms were treated with VP-16-213 alone or in combination with cis-platinum, bleomycin, and frequently Adriamycin. All had prior chemotherapy, which in most was extensive. There were 14 complete and 15 partial remissions. Five of the patients with partial remission were rendered disease free by resection of residual tumor. Eleven remain disease free from 6 +-23+ months. Toxicity was considerable. One-third were hospitalized for fever and granulocytopenia and four had life-threatening thrombocytopenia. There was one drug-related death. VP-16 is an active drug in germinal neoplasms. It appears to be an important component of 'salvage' regimens for refractory patients, but severe toxicity may ensue.

Original languageEnglish
Pages (from-to)2154-2158
Number of pages5
JournalCancer
Volume46
Issue number10
DOIs
StatePublished - 1980

Fingerprint

Salvage Therapy
Etoposide
Neoplasms
Agranulocytosis
Bleomycin
Residual Neoplasm
Thrombocytopenia
Pharmaceutical Preparations
Doxorubicin
Cisplatin
Fever
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

VP-16-213 salvage therapy for refractory germinal neoplasms. / Williams, S. D.; Einhorn, Lawrence; Greco, F. A.; Oldham, R.; Fletcher, R.

In: Cancer, Vol. 46, No. 10, 1980, p. 2154-2158.

Research output: Contribution to journalArticle

Williams, S. D. ; Einhorn, Lawrence ; Greco, F. A. ; Oldham, R. ; Fletcher, R. / VP-16-213 salvage therapy for refractory germinal neoplasms. In: Cancer. 1980 ; Vol. 46, No. 10. pp. 2154-2158.
@article{9b900daa60614bdbb4dc477c5f46c79a,
title = "VP-16-213 salvage therapy for refractory germinal neoplasms",
abstract = "Thirty-three patients with advanced refractory germinal neoplasms were treated with VP-16-213 alone or in combination with cis-platinum, bleomycin, and frequently Adriamycin. All had prior chemotherapy, which in most was extensive. There were 14 complete and 15 partial remissions. Five of the patients with partial remission were rendered disease free by resection of residual tumor. Eleven remain disease free from 6 +-23+ months. Toxicity was considerable. One-third were hospitalized for fever and granulocytopenia and four had life-threatening thrombocytopenia. There was one drug-related death. VP-16 is an active drug in germinal neoplasms. It appears to be an important component of 'salvage' regimens for refractory patients, but severe toxicity may ensue.",
author = "Williams, {S. D.} and Lawrence Einhorn and Greco, {F. A.} and R. Oldham and R. Fletcher",
year = "1980",
doi = "10.1002/1097-0142(19801115)46:10<2154::AID-CNCR2820461008>3.0.CO;2-3",
language = "English",
volume = "46",
pages = "2154--2158",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - VP-16-213 salvage therapy for refractory germinal neoplasms

AU - Williams, S. D.

AU - Einhorn, Lawrence

AU - Greco, F. A.

AU - Oldham, R.

AU - Fletcher, R.

PY - 1980

Y1 - 1980

N2 - Thirty-three patients with advanced refractory germinal neoplasms were treated with VP-16-213 alone or in combination with cis-platinum, bleomycin, and frequently Adriamycin. All had prior chemotherapy, which in most was extensive. There were 14 complete and 15 partial remissions. Five of the patients with partial remission were rendered disease free by resection of residual tumor. Eleven remain disease free from 6 +-23+ months. Toxicity was considerable. One-third were hospitalized for fever and granulocytopenia and four had life-threatening thrombocytopenia. There was one drug-related death. VP-16 is an active drug in germinal neoplasms. It appears to be an important component of 'salvage' regimens for refractory patients, but severe toxicity may ensue.

AB - Thirty-three patients with advanced refractory germinal neoplasms were treated with VP-16-213 alone or in combination with cis-platinum, bleomycin, and frequently Adriamycin. All had prior chemotherapy, which in most was extensive. There were 14 complete and 15 partial remissions. Five of the patients with partial remission were rendered disease free by resection of residual tumor. Eleven remain disease free from 6 +-23+ months. Toxicity was considerable. One-third were hospitalized for fever and granulocytopenia and four had life-threatening thrombocytopenia. There was one drug-related death. VP-16 is an active drug in germinal neoplasms. It appears to be an important component of 'salvage' regimens for refractory patients, but severe toxicity may ensue.

UR - http://www.scopus.com/inward/record.url?scp=0019163028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019163028&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19801115)46:10<2154::AID-CNCR2820461008>3.0.CO;2-3

DO - 10.1002/1097-0142(19801115)46:10<2154::AID-CNCR2820461008>3.0.CO;2-3

M3 - Article

C2 - 6159062

AN - SCOPUS:0019163028

VL - 46

SP - 2154

EP - 2158

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -